Human Pluripotent Stem Cells for Spinal Cord Injury

Author(s): Maryam Farzaneh*, Amir Anbiyaiee, Seyed Esmaeil Khoshnam*.

Journal Name: Current Stem Cell Research & Therapy

Volume 15 , Issue 2 , 2020

Become EABM
Become Reviewer

Abstract:

Spinal cord injury (SCI) as a serious public health issue and neurological insult is one of the most severe cause of long-term disability. To date, a variety of techniques have been widely developed to treat central nervous system injury. Currently, clinical treatments are limited to surgical decompression and pharmacotherapy. Because of their negative effects and inefficiency, novel therapeutic approaches are required in the management of SCI. Improvement and innovation of stem cell-based therapies have a huge potential for biological and future clinical applications. Human pluripotent stem cells (hPSCs) including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are defined by their abilities to divide asymmetrically, self-renew and ultimately differentiate into various cell lineages. There are considerable research efforts to use various types of stem cells, such as ESCs, neural stem cells (NSCs), and mesenchymal stem cells (MSCs) in the treatment of patients with SCI. Moreover, the use of patient-specific iPSCs holds great potential as an unlimited cell source for generating in vivo models of SCI. In this review, we focused on the potential of hPSCs in treating SCI.

Keywords: Spinal cord injury, stem cell therapy, human pluripotent stem cells, embryonic stem cells, induced pluripotent stem cells, regenerative medicine.

[1]
Tu S, Tu J. Stem Cell Therapy for Spinal Cord InjuryNeurological Regeneration. Springer 2017; pp. 137-58.
[http://dx.doi.org/10.1007/978-3-319-33720-3_8]
[2]
O’Shea TM, Burda JE, Sofroniew MV. Cell biology of spinal cord injury and repair. J Clin Invest 2017; 127(9): 3259-70.
[http://dx.doi.org/10.1172/JCI90608] [PMID: 28737515]
[3]
Jin MC, Medress ZA, Azad TD, Doulames VM, Veeravagu A. Stem cell therapies for acute spinal cord injury in humans: A review. Neurosurg Focus 2019; 46(3)E10
[http://dx.doi.org/10.3171/2018.12.FOCUS18602] [PMID: 30835679]
[4]
Gazdic M, Volarevic V, Harrell CR, et al. Stem cells therapy for spinal cord injury. Int J Mol Sci 2018; 19(4): 1039.
[http://dx.doi.org/10.3390/ijms19041039] [PMID: 29601528]
[5]
Cano-Torres EA, González-Cantú A, Hinojosa-Garza G, Castilleja-Leal F. Immobilization induced hypercalcemia. Clin Cases Miner Bone Metab 2016; 13(1): 46-7.
[PMID: 27252745]
[6]
Wutte C, Klein B, Becker J, et al. Earlier decompression (< 8 hours) results in better neurological and functional outcome after traumatic thoracolumbar spinal cord injury. J Neurotrauma 2019; 36(12): 2020-7.
[http://dx.doi.org/10.1089/neu.2018.6146] [PMID: 30489193]
[7]
ter Wengel PV, et al. The impact of early (24h) surgical decompression on neurological recovery in thoracic spinal cord injury: a meta-analysis. J Neurotrauma 2019; 36(18): 2609-17.
[8]
Zhang Y, Lv Y, Ji W, Zhou R, Gao S, Zhou F. Therapeutic hypothermia effectively reduces elevated extracellular ascorbate concentrations caused by acute spinal cord injury. Artif Cells Nanomed Biotechnol 2019; 47(1): 22-9.
[http://dx.doi.org/10.1080/21691401.2018.1541136] [PMID: 30526134]
[9]
Krieg SM. Spinal cord injurySpine Surgery. Springer 2019; pp. 243-51.
[http://dx.doi.org/10.1007/978-3-319-98875-7_31]
[10]
Wallisch JS, Fink EL. Therapeutic Hypothermia in the Pediatric ICUPediatric Critical Care. Springer 2019; pp. 323-39.
[http://dx.doi.org/10.1007/978-3-319-96499-7_20]
[11]
Riessland M. Is there hope for spinal muscular atrophy synthetic pharmacotherapy?. Taylor & Francis 2019.
[http://dx.doi.org/10.1080/14656566.2019.1595585]
[12]
Guercio JR, Kralic JE, Marrotte EJ, James ML. Spinal cord injury pharmacotherapy: Current research & development and competitive commercial landscape as of 2015. J Spinal Cord Med 2019; 42(1): 102-22.
[http://dx.doi.org/10.1080/10790268.2018.1439803] [PMID: 29485334]
[13]
Muheremu A, Peng J, Ao Q. Stem cell based therapies for spinal cord injury. Tissue Cell 2016; 48(4): 328-33.
[http://dx.doi.org/10.1016/j.tice.2016.05.008] [PMID: 27318871]
[14]
Wu S, FitzGerald KT, Giordano J. On the Viability and Potential Value of Stem Cells for Repair and Treatment of Central Neurotrauma: Overview and Speculations. Front Neurol 2018; 9: 602.
[http://dx.doi.org/10.3389/fneur.2018.00602] [PMID: 30150968]
[15]
Lin H. Cell biology of stem cells: An enigma of asymmetry and self-renewal. J Cell Biol 2008; 180(2): 257-60.
[http://dx.doi.org/10.1083/jcb.200712159] [PMID: 18227277]
[16]
Babiarz JE, Blelloch R. Small RNAs–their biogenesis, regulation and function in embryonic stem cells NISEB Journal 2019; 12(4)
[17]
Rowe RG, Daley GQ. Induced pluripotent stem cells in disease modelling and drug discovery. Nat Rev Genet 2019; 20(7): 377-88.
[http://dx.doi.org/10.1038/s41576-019-0100-z] [PMID: 30737492]
[18]
Shi Y, Inoue H, Wu JC, Yamanaka S. Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov 2017; 16(2): 115-30.
[http://dx.doi.org/10.1038/nrd.2016.245] [PMID: 27980341]
[19]
Teng YD. Functional multipotency of stem cells: Biological traits gleaned from neural progeny studiesSeminars in cell & developmental biology. Elsevier 2019.
[http://dx.doi.org/10.1016/j.semcdb.2019.02.002]
[20]
Sandquist EJ, Sakaguchi DS. Adult neural stem cell plasticity. Neural Regen Res 2019; 14(2): 256-7.
[http://dx.doi.org/10.4103/1673-5374.244785] [PMID: 30531005]
[21]
Gazit Z, et al. Mesenchymal stem cellsPrinciples of regenerative medicine. Elsevier 2019; pp. 205-18.
[http://dx.doi.org/10.1016/B978-0-12-809880-6.00014-X]
[22]
Farzaneh M, Rahimi F, Alishahi M, Khoshnam SE. Paracrine mechanisms involved in mesenchymal stem cell differentiation into cardiomyocytes. Curr Stem Cell Res Ther 2019; 14(1): 9-13.
[http://dx.doi.org/10.2174/1574888X13666180821160421] [PMID: 30152289]
[23]
Singh VK, Saini A, Kalsan M, Kumar N, Chandra R. Describing the stem cell potency: the various methods of functional assessment and in silico diagnostics. Front Cell Dev Biol 2016; 4: 134.
[http://dx.doi.org/10.3389/fcell.2016.00134] [PMID: 27921030]
[24]
Farzaneh M, Khoshnam S, Mozdziak P. Concise Review: Avian Multipotent Stem Cells as a Novel Tool for Investigating Cell-Based Therapies. J Dairy Vet Anim Res 2017; 5(1): 00125.
[http://dx.doi.org/10.15406/jdvar.2017.05.00125]
[25]
Ehninger A. Genetic modified pluri-or multipotent stem cells and uses thereof Google Patents. 2019.
[26]
Medvedev SP, Shevchenko AI, Zakian SM. Induced Pluripotent Stem Cells: Problems and Advantages when Applying them in Regenerative Medicine Acta naturae 2010; 2(2): 18-28.
[27]
Kimbrel EA, Lanza R. Pluripotent stem cells: the last 10 years. Regen Med 2016; 11(8): 831-47.
[http://dx.doi.org/10.2217/rme-2016-0117] [PMID: 27908220]
[28]
Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors cell 2007; 131(5): 861-72.
[29]
Sayed N, Liu C, Wu JC. Translation of human-induced pluripotent stem cells: From clinical trial in a dish to precision medicine. J Am Coll Cardiol 2016; 67(18): 2161-76.
[http://dx.doi.org/10.1016/j.jacc.2016.01.083] [PMID: 27151349]
[30]
Khandany B, Heidari MM, Khatami M. Induced pluripotent stem cells (iPSCs) based approaches for hematopoietic cancer therapy. Iran J Ped Hematol Oncol 2019; 9(2): 117-30.
[http://dx.doi.org/10.18502/ijpho.v9i2.611]
[31]
Aronoff GM. What do we know about the pathophysiology of chronic pain?: Implications for treatment considerations. Med Clin North Am 2016; 100(1): 31-42.
[http://dx.doi.org/10.1016/j.mcna.2015.08.004] [PMID: 26614717]
[32]
Bartus K, Galino J, James ND, et al. Neuregulin-1 controls an endogenous repair mechanism after spinal cord injury. Brain 2016; 139(Pt 5): 1394-416.
[http://dx.doi.org/10.1093/brain/aww039] [PMID: 26993800]
[33]
Jutzeler CR, Huber E, Callaghan MF, et al. Association of pain and CNS structural changes after spinal cord injury. Sci Rep 2016; 6: 18534.
[http://dx.doi.org/10.1038/srep18534] [PMID: 26732942]
[34]
Ulndreaj A, Badner A, Fehlings MG. Promising neuroprotective strategies for traumatic spinal cord injury with a focus on the differential effects among anatomical levels of injury. F1000 Res 2017; 6: 1907.
[http://dx.doi.org/10.12688/f1000research.11633.1] [PMID: 29152227]
[35]
Sofroniew MV. Dissecting spinal cord regeneration. Nature 2018; 557(7705): 343-50.
[http://dx.doi.org/10.1038/s41586-018-0068-4] [PMID: 29769671]
[36]
Ambrozaitis KV, Kontautas E, Spakauskas B, Vaitkaitis D. [Pathophysiology of acute spinal cord injury]. Medicina (Kaunas) 2006; 42(3): 255-61.
[PMID: 16607070]
[37]
Maikos JT, Shreiber DI. Immediate damage to the blood-spinal cord barrier due to mechanical trauma. J Neurotrauma 2007; 24(3): 492-507.
[http://dx.doi.org/10.1089/neu.2006.0149] [PMID: 17402855]
[38]
Freund P, Curt A, Friston K, Thompson A. Tracking changes following spinal cord injury: Insights from neuroimaging. Neuroscientist 2013; 19(2): 116-28.
[http://dx.doi.org/10.1177/1073858412449192] [PMID: 22730072]
[39]
Oh SK, Jeon SR. Current concept of stem cell therapy for spinal cord injury: A review. Korean J Neurotrauma 2016; 12(2): 40-6.
[http://dx.doi.org/10.13004/kjnt.2016.12.2.40] [PMID: 27857906]
[40]
Curt A, et al. The Human Spinal Cord is a Promising Target for Allogeneic Neural Stem Cell Transplantation Available at SSRN 3352503 2019..
[http://dx.doi.org/10.2139/ssrn.3352503]
[41]
Lee D-Y, Park YJ, Song SY, Hwang SC, Kim KT, Kim DH. The importance of early surgical decompression for acute traumatic spinal cord injury. Clin Orthop Surg 2018; 10(4): 448-54.
[http://dx.doi.org/10.4055/cios.2018.10.4.448] [PMID: 30505413]
[42]
Wang J, Pearse DD. Therapeutic Hypothermia in Spinal Cord Injury: The Status of Its Use and Open Questions. Int J Mol Sci 2015; 16(8): 16848-79.
[http://dx.doi.org/10.3390/ijms160816848] [PMID: 26213924]
[43]
Yue JK, Tsolinas RE, Burke JF, et al. Vasopressor support in managing acute spinal cord injury: current knowledge. J Neurosurg Sci 2019; 63(3): 308-17.
[44]
Hayta E, Elden H. Acute spinal cord injury: A review of pathophysiology and potential of non-steroidal anti-inflammatory drugs for pharmacological intervention. J Chem Neuroanat 2018; 87: 25-31.
[http://dx.doi.org/10.1016/j.jchemneu.2017.08.001] [PMID: 28803968]
[45]
Yu D, Silva GA. Stem cell sources and therapeutic approaches for central nervous system and neural retinal disorders. Neurosurg Focus 2008; 24(3-4)E11
[http://dx.doi.org/10.3171/FOC/2008/24/3-4/E10] [PMID: 18341387]
[46]
Niakan KK, Han J, Pedersen RA, Simon C, Pera RA. Human pre-implantation embryo development. Development 2012; 139(5): 829-41.
[http://dx.doi.org/10.1242/dev.060426] [PMID: 22318624]
[47]
Boroviak T, Nichols J. The birth of embryonic pluripotency. Philos Trans R Soc Lond B Biol Sci 2014; 369(1657)20130541
[http://dx.doi.org/10.1098/rstb.2013.0541] [PMID: 25349450]
[48]
Shand J, Berg J, Bogue C. Human embryonic stem cell (hESC) and human embryo research. Pediatrics 2012; 130(5): 972-7.
[http://dx.doi.org/10.1542/peds.2012-2482] [PMID: 23109685]
[49]
Farzaneh M, Derakhshan Z, Hallajzadeh J, Sarani NH, Nejabatdoust A, Khoshnam SE. Suppression of TGF-β and ERK signaling pathways as a new strategy to provide rodent and non-rodent pluripotent stem cells. Curr Stem Cell Res Ther 2019; 14(6): 466-73.
[http://dx.doi.org/10.2174/1871527318666190314110529] [PMID: 30868962]
[50]
Farzaneh M, Alishahi M, Derakhshan Z, Sarani NH, Attari F, Khoshnam SE. The Expression and Functional Roles of miRNAs in Embryonic and Lineage-Specific Stem Cells. Curr Stem Cell Res Ther 2019; 14(3): 278-89.
[http://dx.doi.org/10.2174/1574888X14666190123162402] [PMID: 30674265]
[51]
Huang Y, Liang P, Liu D, Huang J, Songyang Z. Telomere regulation in pluripotent stem cells. Protein Cell 2014; 5(3): 194-202.
[http://dx.doi.org/10.1007/s13238-014-0028-1] [PMID: 24563217]
[52]
Satyavathi M, Keerthi K, Amulya K, Susmitha G, Sankar PR, Babu PS. Novel challenges of stem cell therapy in neurodegenerative disorders. Indian J Res Pharm Biotechnol 2018; 6(2): 54-8.
[53]
Prajumwongs P, et al. Human embryonic stem cells: A model for the study of neural development and neurological diseases. Stem Cells Int 2016; 2016 2958210
[http://dx.doi.org/10.1155/2016/2958210]
[54]
Shroff G, Dhanda Titus J, Shroff R. A review of the emerging potential therapy for neurological disorders: human embryonic stem cell therapy. Am J Stem Cells 2017; 6(1): 1-12.
[PMID: 28533935]
[55]
McDonald JW, Liu XZ, Qu Y, et al. Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord. Nat Med 1999; 5(12): 1410-2.
[http://dx.doi.org/10.1038/70986] [PMID: 10581084]
[56]
Taupin P. Adult neural stem cells, neurogenic niches, and cellular therapy. Stem Cell Rev 2006; 2(3): 213-9.
[http://dx.doi.org/10.1007/s12015-006-0049-0] [PMID: 17625257]
[57]
Bond AM, Ming GL, Song H. Adult mammalian neural stem cells and neurogenesis: five decades later. Cell Stem Cell 2015; 17(4): 385-95.
[http://dx.doi.org/10.1016/j.stem.2015.09.003] [PMID: 26431181]
[58]
Nutt SE, Chang EA, Suhr ST, et al. Caudalized human iPSC-derived neural progenitor cells produce neurons and glia but fail to restore function in an early chronic spinal cord injury model. Exp Neurol 2013; 248: 491-503.
[http://dx.doi.org/10.1016/j.expneurol.2013.07.010] [PMID: 23891888]
[59]
Okada Y, Matsumoto A, Shimazaki T, et al. Spatiotemporal recapitulation of central nervous system development by murine embryonic stem cell-derived neural stem/progenitor cells. Stem Cells 2008; 26(12): 3086-98.
[http://dx.doi.org/10.1634/stemcells.2008-0293] [PMID: 18757299]
[60]
Shao F, Liu C. Revisit the candidacy of brain cell types as the Cell (s) of origin for human high-grade glioma. Front Mol Neurosci 2018; 11: 48.
[http://dx.doi.org/10.3389/fnmol.2018.00048] [PMID: 29515370]
[61]
Keirstead HS, Nistor G, Bernal G, et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J Neurosci 2005; 25(19): 4694-705.
[http://dx.doi.org/10.1523/JNEUROSCI.0311-05.2005] [PMID: 15888645]
[62]
Egawa N, Takase H, Josephine L, Takahashi R, Arai K. Clinical application of oligodendrocyte precursor cells for cell-based therapy. Brain Circ 2016; 2(3): 121-5.
[http://dx.doi.org/10.4103/2394-8108.192515] [PMID: 30276286]
[63]
Sharp J, Frame J, Siegenthaler M, Nistor G, Keirstead HS. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants improve recovery after cervical spinal cord injury. Stem Cells 2010; 28(1): 152-63.
[PMID: 19877167]
[64]
Wirth III ED, Lebkowski JS. Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury. Google Patents 2019.
[65]
Marton RM, Miura Y, Sloan SA, et al. Differentiation and maturation of oligodendrocytes in human three-dimensional neural cultures. Nat Neurosci 2019; 22(3): 484-91.
[66]
Manley NC, Priest CA, Denham J, Wirth ED III, Lebkowski JS. Human embryonic stem cell‐derived oligodendrocyte progenitor cells: preclinical efficacy and safety in cervical spinal cord injury. Stem Cells Transl Med 2017; 6(10): 1917-29.
[http://dx.doi.org/10.1002/sctm.17-0065] [PMID: 28834391]
[67]
Erceg S, Laínez S, Ronaghi M, et al. Differentiation of human embryonic stem cells to regional specific neural precursors in chemically defined medium conditions. PLoS One 2008; 3(5)e2122
[http://dx.doi.org/10.1371/journal.pone.0002122] [PMID: 18461168]
[68]
Farzaneh M, Attari F, Mozdziak PE, Khoshnam SE. The evolution of chicken stem cell culture methods. Br Poult Sci 2017; 58(6): 681-6.
[http://dx.doi.org/10.1080/00071668.2017.1365354] [PMID: 28840744]
[69]
Nistor G, Siegenthaler MM, Poirier SN, et al. Derivation of high purity neuronal progenitors from human embryonic stem cells. PLoS One 2011; 6(6) e20692
[http://dx.doi.org/10.1371/journal.pone.0020692] [PMID: 21673956]
[70]
Moreno-Manzano V, Rodríguez-Jiménez FJ, García-Roselló M, et al. Activated spinal cord ependymal stem cells rescue neurological function. Stem Cells 2009; 27(3): 733-43.
[http://dx.doi.org/10.1002/stem.24] [PMID: 19259940]
[71]
Kumamaru H, Kadoya K, Adler AF, et al. Generation and post-injury integration of human spinal cord neural stem cells. Nat Methods 2018; 15(9): 723-31.
[http://dx.doi.org/10.1038/s41592-018-0074-3] [PMID: 30082899]
[72]
Jones I, Novikova LN, Novikov LN, et al. Regenerative effects of human embryonic stem cell-derived neural crest cells for treatment of peripheral nerve injury. J Tissue Eng Regen Med 2018; 12(4): e2099-109.
[http://dx.doi.org/10.1002/term.2642] [PMID: 29327452]
[73]
Jendelova P, Sykova E, Erceg S. Neural stem cells derived from human-induced pluripotent stem cells and their use in models of CNS injury Human Neural Stem Cells. Springer 2018; pp. 89-102.
[http://dx.doi.org/10.1007/978-3-319-93485-3_3]
[74]
Farzaneh M, Attari F, Khoshnam SE. Concise review: LIN28/let-7 signaling, a critical double-negative feedback loop during pluripotency, reprogramming, and Tumorigenicity. Cell Reprogram 2017; 19(5): 289-93.
[http://dx.doi.org/10.1089/cell.2017.0015] [PMID: 28846452]
[75]
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126(4): 663-76.
[http://dx.doi.org/10.1016/j.cell.2006.07.024] [PMID: 16904174]
[76]
Chun YS, Chaudhari P, Jang Y-Y. Applications of patient-specific induced pluripotent stem cells; focused on disease modeling, drug screening and therapeutic potentials for liver disease. Int J Biol Sci 2010; 6(7): 796-805.
[http://dx.doi.org/10.7150/ijbs.6.796] [PMID: 21179587]
[77]
Jiang Z, Han Y, Cao X. Induced pluripotent stem cell (iPSCs) and their application in immunotherapy. Cell Mol Immunol 2014; 11(1): 17-24.
[http://dx.doi.org/10.1038/cmi.2013.62] [PMID: 24336163]
[78]
Khazaei M, Siddiqui AM, Fehlings MG. The potential for iPS-derived stem cells as a therapeutic strategy for spinal cord injury: opportunities and challenges. J Clin Med 2014; 4(1): 37-65.
[http://dx.doi.org/10.3390/jcm4010037] [PMID: 26237017]
[79]
Ramotowski C, Qu X, Villa‐Diaz LG. Progress in the use of induced pluripotent stem cell-derived neural cells for traumatic spinal cord injuries in animal populations. Meta-Analysis and Review Stem Cells Transl Med 2019; 8(7): 681-93.
[80]
Khazaei M, Ahuja CS, Fehlings MG. Induced pluripotent stem cells for traumatic spinal cord injury. Front Cell Dev Biol 2017; 4: 152.
[http://dx.doi.org/10.3389/fcell.2016.00152] [PMID: 28154814]
[81]
Park A, Hong P, Won ST, et al. Sendai virus, an RNA virus with no risk of genomic integration, delivers CRISPR/Cas9 for efficient gene editing. Mol Ther Methods Clin Dev 2016; 3: 16057.
[http://dx.doi.org/10.1038/mtm.2016.57] [PMID: 27606350]
[82]
Pesaresi M, Sebastian-Perez R, Cosma MP. Dedifferentiation, transdifferentiation and cell fusion: in vivo reprogramming strategies for regenerative medicine. FEBS J 2019; 286(6): 1074-93.
[http://dx.doi.org/10.1111/febs.14633] [PMID: 30103260]
[83]
Deng X-Y, Wang H, Wang T, et al. Non-viral methods for generating integration-free, induced pluripotent stem cells. Curr Stem Cell Res Ther 2015; 10(2): 153-8.
[http://dx.doi.org/10.2174/1574888X09666140923101914] [PMID: 25248676]
[84]
Lee C, Robinson M, Willerth SM. Direct reprogramming of glioblastoma cells into neurons using small molecules. ACS Chem Neurosci 2018; 9(12): 3175-85.
[http://dx.doi.org/10.1021/acschemneuro.8b00365] [PMID: 30091580]
[85]
Zhou J, Sun J. A Revolution in Reprogramming: Small Molecules. Curr Mol Med 2019; 19(2): 77-90.
[http://dx.doi.org/10.2174/1566524019666190325113945] [PMID: 30914022]
[86]
Miura K, Okada Y, Aoi T, et al. Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol 2009; 27(8): 743-5.
[http://dx.doi.org/10.1038/nbt.1554] [PMID: 19590502]
[87]
Zhang Y, Pak C, Han Y, et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 2013; 78(5): 785-98.
[http://dx.doi.org/10.1016/j.neuron.2013.05.029] [PMID: 23764284]
[88]
Hallett PJ, Deleidi M, Astradsson A, et al. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson’s disease. Cell Stem Cell 2015; 16(3): 269-74.
[http://dx.doi.org/10.1016/j.stem.2015.01.018] [PMID: 25732245]
[89]
Nicholas CR, Chen J, Tang Y, et al. Functional maturation of hPSC-derived forebrain interneurons requires an extended timeline and mimics human neural development. Cell Stem Cell 2013; 12(5): 573-86.
[http://dx.doi.org/10.1016/j.stem.2013.04.005] [PMID: 23642366]
[90]
Sareen D, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med 2013; 5(208) 208ra149
[http://dx.doi.org/10.1126/scitranslmed.3007529]
[91]
Karumbayaram S, Novitch BG, Patterson M, et al. Directed differentiation of human-induced pluripotent stem cells generates active motor neurons. Stem Cells 2009; 27(4): 806-11.
[http://dx.doi.org/10.1002/stem.31] [PMID: 19350680]
[92]
Sances S, Bruijn LI, Chandran S, et al. Modeling ALS with motor neurons derived from human induced pluripotent stem cells. Nat Neurosci 2016; 19(4): 542-53.
[http://dx.doi.org/10.1038/nn.4273] [PMID: 27021939]
[93]
Salewski RP, Mitchell RA, Li L, et al. Transplantation of induced pluripotent stem cell‐derived neural stem cells mediate functional recovery following thoracic spinal cord injury through remyelination of axons. Stem Cells Transl Med 2015; 4(7): 743-54.
[http://dx.doi.org/10.5966/sctm.2014-0236] [PMID: 25979861]
[94]
Amemori T, Ruzicka J, Romanyuk N, Jhanwar-Uniyal M, Sykova E, Jendelova P. Comparison of intraspinal and intrathecal implantation of induced pluripotent stem cell-derived neural precursors for the treatment of spinal cord injury in rats. Stem Cell Res Ther 2015; 6(1): 257.
[http://dx.doi.org/10.1186/s13287-015-0255-2] [PMID: 26696415]
[95]
Fan L, et al. Directing induced pluripotent stem cell derived neural stem cell fate with a three-dimensional biomimetic hydrogel for spinal cord injury repair 2018; 10(21): 17742-55.
[96]
Nagoshi N, Okano H. Applications of induced pluripotent stem cell technologies in spinal cord injury. J Neurochem 2017; 141(6): 848-60.
[http://dx.doi.org/10.1111/jnc.13986] [PMID: 28199003]
[97]
Nistor GI, Totoiu MO, Haque N, Carpenter MK, Keirstead HS. Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation. Glia 2005; 49(3): 385-96.
[http://dx.doi.org/10.1002/glia.20127] [PMID: 15538751]
[98]
Faulkner J, Keirstead HS. Human embryonic stem cell-derived oligodendrocyte progenitors for the treatment of spinal cord injury. Transpl Immunol 2005; 15(2): 131-42.
[http://dx.doi.org/10.1016/j.trim.2005.09.007] [PMID: 16412957]
[99]
Zhang YW, Denham J, Thies RS. Oligodendrocyte progenitor cells derived from human embryonic stem cells express neurotrophic factors. Stem Cells Dev 2006; 15(6): 943-52.
[http://dx.doi.org/10.1089/scd.2006.15.943] [PMID: 17253955]
[100]
Izrael M, Zhang P, Kaufman R, et al. Human oligodendrocytes derived from embryonic stem cells: Effect of noggin on phenotypic differentiation in vitro and on myelination in vivo. Mol Cell Neurosci 2007; 34(3): 310-23.
[http://dx.doi.org/10.1016/j.mcn.2006.11.008] [PMID: 17196394]
[101]
Schaumburg C, O’Hara BA, Lane TE, Atwood WJ. Human embryonic stem cell-derived oligodendrocyte progenitor cells express the serotonin receptor and are susceptible to JC virus infection. J Virol 2008; 82(17): 8896-9.
[http://dx.doi.org/10.1128/JVI.00406-08] [PMID: 18579595]
[102]
Hu B-Y, Du ZW, Li XJ, Ayala M, Zhang SC. Human oligodendrocytes from embryonic stem cells: conserved SHH signaling networks and divergent FGF effects. Development 2009; 136(9): 1443-52.
[http://dx.doi.org/10.1242/dev.029447] [PMID: 19363151]
[103]
Erceg S, Ronaghi M, Oria M, et al. Transplanted oligodendrocytes and motoneuron progenitors generated from human embryonic stem cells promote locomotor recovery after spinal cord transection. Stem Cells 2010; 28(9): 1541-9.
[http://dx.doi.org/10.1002/stem.489] [PMID: 20665739]
[104]
Son EY, Ichida JK, Wainger BJ, et al. Conversion of mouse and human fibroblasts into functional spinal motor neurons. Cell Stem Cell 2011; 9(3): 205-18.
[http://dx.doi.org/10.1016/j.stem.2011.07.014] [PMID: 21852222]
[105]
All AH, Bazley FA, Gupta S, et al. Human embryonic stem cell-derived oligodendrocyte progenitors aid in functional recovery of sensory pathways following contusive spinal cord injury. PLoS One 2012; 7(10)e47645
[http://dx.doi.org/10.1371/journal.pone.0047645] [PMID: 23091637]
[106]
Takazawa T, Croft GF, Amoroso MW, Studer L, Wichterle H, Macdermott AB. Maturation of spinal motor neurons derived from human embryonic stem cells. PLoS One 2012; 7(7)e40154
[http://dx.doi.org/10.1371/journal.pone.0040154] [PMID: 22802953]
[107]
Priest CA, Manley NC, Denham J, Wirth ED III, Lebkowski JS. Preclinical safety of human embryonic stem cell-derived oligodendrocyte progenitors supporting clinical trials in spinal cord injury. Regen Med 2015; 10(8): 939-58.
[http://dx.doi.org/10.2217/rme.15.57] [PMID: 26345388]
[108]
Führmann T, Tam RY, Ballarin B, et al. Injectable hydrogel promotes early survival of induced pluripotent stem cell-derived oligodendrocytes and attenuates longterm teratoma formation in a spinal cord injury model. Biomaterials 2016; 83: 23-36.
[http://dx.doi.org/10.1016/j.biomaterials.2015.12.032] [PMID: 26773663]
[109]
Fandel TM, Trivedi A, Nicholas CR, et al. Transplanted human stem cell-derived interneuron precursors mitigate mouse bladder dysfunction and central neuropathic pain after spinal cord injury. Cell Stem Cell 2016; 19(4): 544-57.
[http://dx.doi.org/10.1016/j.stem.2016.08.020] [PMID: 27666009]
[110]
Kim D-S, Jung SJ, Lee JS, et al. Rapid generation of OPC-like cells from human pluripotent stem cells for treating spinal cord injury. Exp Mol Med 2017; 49(7) e361
[http://dx.doi.org/10.1038/emm.2017.106] [PMID: 28751784]
[111]
Manley NC, Priest CA, Denham J, Wirth ED III, Lebkowski JS. Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cells: Preclinical Efficacy and Safety in Cervical Spinal Cord Injury. Stem Cells Transl Med 2017; 6(10): 1917-29.
[http://dx.doi.org/10.1002/sctm.17-0065] [PMID: 28834391]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 2
Year: 2020
Page: [135 - 143]
Pages: 9
DOI: 10.2174/1574362414666191018121658
Price: $65

Article Metrics

PDF: 15
HTML: 3
EPUB: 1
PRC: 1